Synbio International Licenses MD PHD Wellness Nutraceuticals

Synbio International Inc, a company developing AI-driven software for mental health screening, has entered into a strategic licensing agreement with MD PHD Wellness, Inc., a leading nutraceutical developer. The agreement will enable Synbio to commercialize MD PHD Wellness’ proprietary anti-anxiety nutraceutical formulation under the Synbio’s Healing Force™ brand in the United States and Canada.

Under the terms of the agreement, MD PHD Wellness will retain responsibility for product development, manufacturing, quality assurance, and supply chain management. Synbio, on the other hand, will handle branding, marketing, sales, and distribution. The partnership aims to provide Synbio with immediate access to scientifically developed nutraceutical products, accelerating its path to revenue generation.

Claudio Solitario, CEO of Synbio International Inc, expressed optimism about the agreement, stating, "This partnership represents a significant milestone for Synbio, allowing us to participate in the growing nutraceutical market through a portfolio of scientifically validated products. It also provides us with a scalable business model, enabling us to focus on creating shareholder value through brand building and expanding our market presence."

MD PHD Wellness, co-founded by Dr. Robert Lawrence and Dr. David Anderson, is known for its scientific expertise in nutraceutical development. Dr. Lawrence, a physician and scientist with two Ph.D. degrees, has developed multiple nutraceutical products. Dr. Anderson, an experienced physician and scientific consultant, has played a key role in the development of the proprietary formulations licensed to Synbio.

"This agreement is a testament to our commitment to delivering innovative and effective nutraceutical solutions," said Dr. Lawrence. "Working with Synbio, we can now ensure these scientifically developed products reach a broader market and contribute to improving the lives of consumers."

The licensing agreement is part of Synbio International Inc’s broader strategy to build a diversified healthcare company. The company plans to launch its line of nutraceutical products directly to consumers online in 2026, while its AI-driven mental health technologies are in the process of clinical validation. The partnership with MD PHD Wellness is expected to provide Synbio with near-term revenue while the company advances its longer-term healthcare technologies.

Synbio International Inc’s Chief Executive Officer, Claudio Solitario, added, "We believe this partnership will create an efficient and scalable business model. As the global nutraceutical market continues to expand, Synbio is now well-positioned to participate through a growing portfolio of scientifically developed products while advancing our AI-driven mental health technologies."

The agreement, which covers MD PHD Wellness’ flagship anti-anxiety nutraceutical formulation, establishes a framework for the parties to evaluate and commercialize additional proprietary wellness products over time. It underscores Synbio’s commitment to leveraging strategic partnerships to accelerate its growth and diversification in the healthcare sector.